HOPE: A pilot study of psilocybin enhanced group psychotherapy in patients with cancer

It's important to explore the possible use of psychedelic-enhanced group therapy, partly for accessibility reasons. The authors of this exploratory study write: "Context/Objectives Psilocybin-assisted psychotherapy shows promise in treating depression and existential distress in people with serious medical illness. However, its individual-based methodology poses challenges for scaling and resource availability. The HOPE trial (A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients with Cancer) is an Institutional Review Boards-approved open-label feasibility and safety pilot study examining psilocybin-assisted group therapy in cancer patients with a DSM-5 depressive disorder (including major depressive disorder as well as adjustment disorder with depressed mood). We report here the safety and clinical outcome measures including six-months follow up data. Methods Outcome measures were collected at baseline, two-weeks and 26-weeks postintervention. The study involved three group preparatory sessions, one high-dose (25 mg) group psilocybin session, and three group integration sessions with cohorts of four participants over a three-week intervention. Results Twelve participants completed the trial. no serious adverse events attributed to psilocybin occurred. The primary clinical outcome measures of change in symptoms of depression on the clinician administered 17-item-HAM-D showed clinically substantial decrease in HAM-D scores from baseline to the two-week timepoint (21.5–10.09, P < 0.001) and the 26-week timepoint (21.5–14.83, P = 0.006). Six out of 12 participants met criteria for remission at two weeks, as defined by HAM-D < 7, three out 12 demonstrated a clinically significant change (4–6 points), and eight out of twelve demonstrated a clinically substantial change (7–12 points). Conclusion This pilot study demonstrated the safety, feasibility, and possible efficacy of psilocybin-assisted group therapy for cancer patients dealing with depressive symptoms. Based on demonstrated efficacy and significant reductions in therapist time, future investigations with the group therapy model are warranted."

For more psychedelic news and research, visit the psychedelic health professional network homepage.

Previous
Previous

A brief review on the potential of psychedelics for treating Alzheimer’s Disease and related depression

Next
Next

Associations between individual hallucinogens and hallucinogen misuse among U.S. Adults who recently initiated hallucinogen use